BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Announces Launch of MCP Server to Let AI Execute Analytics End-to-End21.1.2026 10:00:00 CET | Press release
Combining MCP, analytics-as-code, and LLMs to automate analytics execution at software speed SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / GoodData, a leader in AI analytics and decision intelligence, today announced the public launch of its MCP Server. As organisations adopt AI in analytics, most tools remain limited to query generation, leaving teams to manually manage metrics, dashboards and business logic. MCP Server moves AI beyond analysis, enabling governed, end-to-end analytics execution and delivering 10-50x faster time to value. The MCP Server is designed for AI developers, and BI and data teams who want to build and manage analytics faster with AI. It allows AI to build and operate analytics in the same way a skilled human team would, but faster and without operational bottlenecks. Using the Model Context Protocol (MCP), AI agents and large language models (LLMs) can connect directly to GoodData and execute analytics across the full lifecycle. They can wor
Kontent.ai Launches AI-Powered SEO and GEO Workflows to Cut Optimization Time by Up to 80% and Optimize Content for Search and Answer Visibility21.1.2026 08:00:00 CET | Press release
Kontent.ai today announced the launch of new agentic SEO and Generative Engine Optimization (GEO) workflows following early results that show organizations reducing the time required to audit and optimize content performance by up to 80 percent while improving organic and answer engine reach without additional media spend. BRNO, CZ / ACCESS Newswire / January 21, 2026 / As content inventories grow into hundreds of thousands of items, search engine optimization (SEO) has become a significant operational cost. Manual audits, spreadsheet-driven updates, and disconnected tooling make it difficult for teams to keep content accurate, structured, and discoverable across both traditional search engines and AI-driven discovery platforms. Kontent.ai's new agentic workflows are designed to change that cost and effort curve. Embedded directly within the CMS, autonomous agents continuously analyze content for missing or inconsistent metadata, unclear structure, outdated terminology, and weak intern
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
Innodata Awarded Prime Contract Position on U.S. Missile Defense Agency's IDIQ SHIELD Program20.1.2026 14:30:00 CET | Press release
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. The SHIELD program is designed to drive rapid innovation and deliver next-generation capabilities that strengthen the nation's multi-layered homeland defense architecture. As part of the broader Golden Dome strategy, this selection positions Innodata to compete for future task orders across research, development, engineering, prototyping, and operations of critical Missile Defense Agency systems that support U.S. national security objectives. The award was made as part of a list of companies eligible to compete under the program publicly announced by the U.S. Government on 15-Jan-26. "We are proud to support our nation's mission to defend the homeland," said Vinay Malkani, SVP Federal of Innodata. "This co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom